The Chinese State Food and Drug Administration (SFDA) has granted approval to Oculus Innovative Sciences' Microcyn hydrogel for moistening, repairing and healing acute and chronic wounds.
The approval is based on the completion of randomized trials for use of Microcyn hydrogel in the treatment of acute wounds, diabetic foot care and post-surgical incisions.
Oculus Innovative Sciences sales vice president Bruce Thornton said the randomized trials in China followed by the SFDA approval provides Oculus with a significant business opportunity underwritten by a very strong partner, Shanghai Sunvic.
The approval enables Shanghai Sunvic to market Microcyn hydrogel in both the over-the-counter and professional healthcare markets in China.
Shanghai Sunvic president Water Chang said the company believe that medical community will embrace an anti-infective technology that is proven both safe and effective in treating topical infection.
"We see the SFDA's rapid approval indicative of a marketplace eager for an anti-infective that works as promised without promoting bacterial resistance as is the case for many of today's antibiotics," Chang added.
